KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Deffered Revenue (2018 - 2023)

Astrazeneca has reported Non-Current Deffered Revenue over the past 6 years, most recently at $7.0 million for Q4 2023.

  • Quarterly results put Non-Current Deffered Revenue at $7.0 million for Q4 2023, down 50.0% from a year ago — trailing twelve months through Dec 2023 was $7.0 million (down 50.0% YoY), and the annual figure for FY2023 was $7.0 million, down 50.0%.
  • Non-Current Deffered Revenue for Q4 2023 was $7.0 million at Astrazeneca, down from $14.0 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for AZN hit a ceiling of $50.0 million in Q4 2019 and a floor of $7.0 million in Q4 2023.
  • Median Non-Current Deffered Revenue over the past 5 years was $26.0 million (2021), compared with a mean of $27.0 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: fell 24.0% in 2020 and later crashed 50.0% in 2023.
  • Astrazeneca's Non-Current Deffered Revenue stood at $50.0 million in 2019, then fell by 24.0% to $38.0 million in 2020, then crashed by 31.58% to $26.0 million in 2021, then tumbled by 46.15% to $14.0 million in 2022, then crashed by 50.0% to $7.0 million in 2023.
  • The last three reported values for Non-Current Deffered Revenue were $7.0 million (Q4 2023), $14.0 million (Q4 2022), and $26.0 million (Q4 2021) per Business Quant data.